LEBENSLAUF PERSÖNLICHE DATEN SCHULBILDUNG STUDIUM PROMOTION BERUFLICHE AUS- UND WEITERBILDUNG

Transkript

1 LEBENSLAUF Dr. med. Ralph Winterhalder Feldmatt 5b 6208 Oberkirch Tel.: PERSÖNLICHE DATEN geboren: Staatsangehörigkeit: Eltern: Familienstand: 10. Dezember 1963 in Zürich Schweiz Willi Winterhalder sel. Kaufmann Erika Winterhalder-Schönemann sel. Lehrerin verheiratet mit Therry Hodel-Winterhalder, 2 Söhne: Kian 2003 und Fionn 2006 SCHULBILDUNG Primarschule Sursee Kantonsschule Sursee, Maturitätstypus B STUDIUM Universität Fribourg und Bern 1989 Staatsexamen Medizin Universität Bern PROMOTION 1989 Thema: Muscle lipofuscin content and satelite cell volume is increased after high altitude exposure in humans. Prof. H. Hoppeler, Universität Bern BERUFLICHE AUS- UND WEITERBILDUNG Assistenzarzt Innere Medizin, Kantonsspital Wolhusen Assistenzarzt Anästhesie, Kantonsspital Luzern Oberarzt Innere Medizin, Kantonsspital Wolhusen Assistenzarzt / Oberarzt Innere Medizin, Kantonsspital Aarau Oberarzt Innere Medizin, Kantonsspital Wolhusen Assistenzarzt, Medizinische Onkologie, Kantonspital Luzern Assistenzarzt Medizinische Onkologie, Universitätspital Basel Research fellow, University of Colorado Cancer Center, Denver Oberarzt Medizinische Onkologie, Luzerner Kantonsspital Luzern Seit 2007 Leitender Arzt Medizinische Onkologie

2 QUALIFIKATIONEN 1989 Staatsexamen Medizin Universität Bern 1989 Doktor der Medizin 1997 Facharzttitel für Innere Medizin FMH 2003 Facharzttitel für Medizinische Onkologie FMH 2009 Zertifikation GCP-ICH PUBLIKATIONEN Martinelli M, Winterhalder R, Cerretelli P, Howald H, Hoppeler H. Muscle lipofuscin content and satellite cell volume is increased after high altitude exposure in humans. Experientia Jul 15;46(7):672-6 Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut Jan;44(1):81-6 Winterhalder RC, Kotantoulas G, Miller YE, Kittelson J, Keith RL, Ingeberg S, Bunn PA, Franklin WA, Hirsch FR. The role of Ki67, p53, EGFR, HER2 and CD31 as possible predictive biomarkers for development of lung cancer in a high-risk population. Proc. IASLC World Conference 2003;273:161 Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA. Chemoprevention of lung cancer from biology to clinical reality. Ann Oncol Feb;15(2): Winterhalder R, Deschler-Marini S, Landmann C, Kann R, Passweg J, Herrmann R, Pless M. Vinorelbine plus low-dose cisplatinum with concomitant radiotherapy for the treatment of locally advanced or inoperable non-metastasized non-small-call lung cancer (stage I- IIIB): a phase II study. Radiother Oncol 2004;73: Merrick D, Winterhalder R, Kittelson J, Franklin W, Kotantoulas G, Ingeberg S, Miller Y, Hirsch F. Increased expression of C-erb-B1 /EGF-R) but not C-erb-B2 (HER2) is assiciated with dysplastic change in bronchial airways: Correlation with increased Ki67, MCM2 and P53 expression. Proc. IASLC World Conference 2005;PD- 057:S83 Merrick DT, Kittelson J, Winterhalder R, Kotantoulas G, Ingeberg S, Keith RL, Kennedy TC, Miller YE, Franklin WA, Hirsch FR. Analysis of c-erbb1/epidermal Growth Factor Receptor and c-erb2/her-2 Expression in Bronchial Dysplasia: Evaluation of Potential Targets for Chemoprevention of Lung Cancer. Clin Cancer Res. 2006, 12: Cuculi F, Gräni R, Winterhalder R. Diminishing liver metastasis of a colonic adenocarcinoma after the removal of a pituitary adenoma. Schweizer Krebs Bulletin 2-06 (26):

3 Zander T, Briner V, Buck F, Winterhalder R. Gastric pneumatosis following polychemotherapy. Eur J Int Med 2007;18: Koeberle D, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, Ruhstaller T, Terraciano L, Neuweiler J, Bieri G, Rust C and Toepfer M. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer Apr 8;98(7): Winterhalder RC, Müller B. Onkologische Notfälle. Praxis 2008;97: Hoesli P, Winterhalder R, Mannhart M, Bressoud A, Exquis B, Delmore G, Monnerat C, Rust C. Selecting oral capecitabine for colorectal cancer (CRC): What influences the decision-making process? Ann Oncol 2008;19:Suppl8:436 Hess V, Pestalozzi B, Ludwig C, Winterhalder R, Lohri A, Jost L, Widmer L, Lee L, Stillhart P, Herrmann R. Gemcitabine, oxaliplatin and capecitabine (GEMOXEL) für patients with advanced pancreatic adenocarcinoma (APC). Preliminary results of an ongoing phase I/II trial. Ann Oncol 2008;19:Suppl8:557P Winterhalder R, Hoesli P, Delmore G, Pederiva S, Bressoud A, Rust C. Compliance with capecitabine: Findings from a prospective cohort analysis. Ann Oncol 2008;19:Suppl8:920P Lohri A, Forrer F, Campana B, Mamot C, Winterhalder R, Herrmann R, Maecke H, Müller-Brand J. Radioimunotherapy (RIT) with 177Lutetium-DOTA-Rituximab (177LU-D-R): A phase I/II study in 30 patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas. Blood 2008; 112: Abstr 3055 Winterhalder R. Das metastasierte Nierenzellkarzinom Onkologische Therapieoptionen. Onkologie 3/2009, 8-12 Winterhalder R. Das Prostatakarzinom: Eine Übersicht aktueller Behandlungsstrategien. Praxis 2009;98: Thürlimann B, Aebi S, Monnerat C, von Moos R, Oehlschlegel C, Pagani O, Perey L, Pestalozzi B, Rochlitz C, Winterhalder R, Zaman K. Using monoclonal antibody therapy in the treatment of breast cancer today: a report from the Swiss Breast Cancer Expert Forum Oncology (Karger, Basel, in press) Sidler D, Thum P, Winterhalder R, Huber G, Haerle SK. Undifferentiated carcinoma of nasopharyngeal type (UCNT): a Swiss single-institutional experience during Swiss Med Wkly May;140(19-20): Winterhalder R, Delmore G, Hoesli PA, Hügli-Dayer A, Mannhart M, Otto F, Pederiva S, van Lier M, Nick S, von Moos R. Impact of different patient management approaches on the control of capecitabine-related adverse events: A prospective cohort analysis. ASCO GI 2010 Proc. Abstr. 495 von Moos R, Delmore G, Hoesli PA, Hügli-Dayer A, Mannhart M, Otto F, Pederiva S, van Lier M, Nick S, Winterhalder R. Initial treatment

4 dose and reasons for dose adjustments during oral capecitabine chemotherapy. ASCO GI 2010 Proc. Abstr. 513 Nagler M, Müller B, Briner V, Winterhalder R. Severe hyperkalemia and bilateral adrenal metastasis. J Oncol. 2009;2009: V. Hess, S. Pratsch, S. Potthast, L. Lee, R. Winterhalder, L. Widmer, C. Cescato, A. Lohri, L. Jost, P. Stillhart, B. Pestalozzi, and R. Herrmann. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial Ann Oncol (2010) 21(12): Richard Cathomas, Christian Rothermundt, Roger von Moos, Daniel Betticher, Ralph Winterhalder, Cornelia Droege, Daniele Siciliano, Dominik Berthold, Miklos Pless, Silke Gillessen on behalf of the Swiss Group for Clinical Cancer Research (SAKK).Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mcrpc) and docetaxel-refractory prostate cancer: a multicenter phase II trial (SAKK 08/07). ASCO 2010, Abstr Ralph Winterhalder, Geoffrey Delmore, Theresa Hardegger, Alexa Urspruch, Klaus Hieke.Cost comparison: capecitabine and oxaliplatin (XELOX) versus 5-fluorouracil (5-FU)/ leucovorin (LV) and oxaliplatin (FOLFOX4) in the adjuvant treatment of patients with colon cancer. ESMO 2010, Abstr. 622P C. Rochlitz, T. Ruhstaller, S. Lerch, C. Spirig, J. Huober, T. Suter, M. Bühlmann, M. Fehr, A. Schönenberger, R. von Moos, R. Winterhalder, D. Rauch, A. Müller, M. Mannhart-Harms, R. Herrmann, B. Cliffe, M. Mayer, K. Zaman, on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as firstline therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06) Ann Oncol 2011; 22(1): Klatt J, Winterhalder R, Arnold W. HPV und das weibliche Genitale. Schweizer Zeitschrift für Onkologie 1/2011; 7-10 Hirschi C, Collen T, Winterhalder R, Gut P. HPV-assoziierte Malignome des Gastrointestinaltrakts. Schweizer Zeitschrift für Onkologie 1/2011; Collen T, Winterhalder R, Diebold J, Müller W, Müller-Beffa L, Thum P. HPV bei Hals-Nasen-Ohren-Tumoren. Schweizer Zeitschrift für Onkologie 1/2011; Winterhalder R, Hoesli P, Pederiva S, Bressoud A, Hermann F, von Moos R. Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology 2011;80:29-33 Huellner MW, Venkatesh SK, Zander T, Winterhalder R, Hennedige TP, Yong WP, Soo RA, Seifert B, Treumann T, Strobel K, Veit- Haibach P. Progrostic value of different CT measurments in therapy response evaluation in patients with colorectal carcinoma and synchronous hepatic metastases at initial staging. ECR 2011, Abstr.B-422 Templeton A, Rothermund C, Cathomas R, Bätschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Dietrich PY, Schiess R, Wild P, Thalmann G, Klingbiel D, Gillessen S. Everolimus first-line therapy in non-rapidly progressive castration

5 resistant prostate cancer (CRPC): A multicenter phase II trial (SAKK 08/08). J Clin Oncol 29: 2011 (suppl; abstr 4588) Winterhalder RC (presenter), Helbling D, Bodoky G, Gautschi O, Sun H, Bosman F, Glor B, Burkhard R, Madlung A, Rauch D, Saletti P, Widmer LA, Borner M, Bärtschi D, Yan P, Koeberle D. Neoadjuvant Chemoradiation (CRT) with or without Panitumumab (Pan) in patients with wild-type KRAS, locally advanced rectal cancer (LARC): A randomized multicenter phase II trial (SAKK 41/07). Ann Oncol 2011; 22 (suppl 5, abstr O-0014) Huellner MW, Hennedige TP, Winterhalder R, Zander T, Venkatesh SK, Yong WP, Soo RA, Seifert B, Treumann TC, Strobel K, Veit- Haibach P. Prognostic value of different CT measurements in early theraly response evaluation in patients with metastatic colorectal cancer. Cancer Imaging 2012, Vol.12 Issue 1, Riklin C, Seystahl K, Hofer S, Happold C, Winterhalder R, Weller M. Antiangiogenic treatment for multiple CNS hemangioblastomas. Onkologie 2012;35:443-5 Cathomas R, Rothermund C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012;18: Helbling D, Bodoky G, Gautschi O, Sun H, Bosman F, Gloor B, Burkhard R. Winterhalder R, Madlung A, Rauch D, Saletti P, Widmer L, Borner M, Baertschi D, Yan P, Benhattar J, Leiundgut E, Bougel S, Koeberle D. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol 2012 Nov 8. (Epub) Toggweiler S, Odermatt Y, Brauchlin A, Zander T, Müller A, Zuber M, Winterhalder R, Erne P. The clinical value of echocardiography to monitor patients undergoing anthracycline chemotherapy. Clin Cardiol 2012 Nov 14 (Epub)